BioNTech
An der Goldgrube 12
Mainz
D-55131
Germany
Tel: 49-6131-9084-0
Fax: 49-6131-9084-390
Website: http://www.biontech.de/
About BioNTech
BioNTech AG is Europe’s largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases.
YEAR FOUNDED:
2008
LEADERSHIP:
Founders: Ugur Sahin and Christoph Huber
Founder and CEO: Ugur Sahin
COO: Sean Marett
CFO: Sierk Poetting
JOBS:
Please click here for BioNTech job opportunities.
CLINICAL TRIAL:
46 articles with BioNTech
-
Sugars that coat proteins are a possible drug target for pancreatitis
6/20/2019
Pancreatitis is an inflammation of the pancreas that accounts for 275,000 hospitalizations in the United States annually.
-
BioSpace Global Roundup, June 20
6/20/2019
Biotech and pharma companies from across Europe and Asia share company and pipeline updates. -
BioNTech and Genmab Initiate First-In-Human Phase I/IIa Trial of Bispecific Antibody DuoBody®-PD-L1x4-1BB in Solid Tumors
6/17/2019
BioNTech SE, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, announced that the first-in-human Phase I/IIa study with DuoBody-PD-L1x4-1BB has been initiated.
-
Companies from across the globe provide updates to their pipelines and businesses, with news from BioNTech, Mologic, Akcea, RedHill, and more.
-
Four biotech companies began trading on the Nasdaq this morning. Here's a look at today’s launches and one rumored IPO.
-
BioNTech Acquires MabVax Therapeutics’ Antibody Assets to Expand Portfolio
5/8/2019
BioNTech SE announced the acquisition of antibody assets and infrastructure from San Diego-based MabVax Therapeutics Holding, Inc., a clinical-stage oncology drug development company.
-
In addition to the planned BioNTech IPO, many other pharma and biotech companies in Europe, Asia and elsewhere shared news for the week.
-
For BioNTech, the IPO will follow a funding round that brought about $270 million into the coffers of the privately-held company.
-
Biotech and pharma companies from across the globe share data and news in a weekly roundup.
-
Messenger RNA (mRNA) is a family of RNA molecules that transport genetic information from DNA to the ribosome, where it specifies the amino acid sequence that creates proteins. In theory, by coding your own mRNA, it should be possible to insert it into the cells and turn them into protein factori...
-
BioNTech to Acquire Antibody Generation Unit of MAB Discovery
1/23/2019
BioNTech AG and MAB Discovery GmbH announced that both partners have entered into a definitive agreement under which BioNTech will acquire MAB Discovery’s operational antibody generation unit.
-
BioNTech AG inked a deal with Munich, Germany’s MAB Discovery GmbH to acquire MAB’s operational antibody generation unit. No financial details were disclosed.
-
Days ahead of the J.P. Morgan Healthcare Conference, Germany-based BioNTech extended its three-year-old collaboration with Sanofi as the companies look to co-develop the first cancer immunotherapy candidate for solid tumors.
-
BioNTech: MammaTyper® Validated as Predictor for Response After Neoadjuvant Chemotherapy (NACT) in Patients with Early Breast Cancer (BC)
11/28/2018
New results from a clinical performance evaluation study of the CE-marked IVD MammaTyper® which were presented at the European Society for Medical Oncology (ESMO) in Munich in October.(1,2)
-
BioNTech and the University of Pennsylvania Enter into Strategic Research Collaboration to Develop mRNA Vaccine Candidates Against Various Infectious Diseases
11/5/2018
New research program between BioNTech and the University of Pennsylvania
-
BioNTech Inks $425 Million Collaboration Deal with Pfizer to Develop mRNA-based Flu Vaccines
8/16/2018
BioNTech, headquartered in Mainz, Germany, and Pfizer, based in New York City, signed a multi-year research-and-development deal to develop mRNA-based flu vaccines. -
BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza
8/16/2018
BioNTech will receive $120 million in upfront, equity and near-term research payments from Pfizer and will be eligible to receive up to $305 million in potential development, regulatory and commercial milestone payments and up to double-digit royalties
-
BioNTech and SMP to evaluate SMP's next generation technology for BioNTech products
8/1/2018
Pursuing a common objective of superior primary packaging for a range of mRNA compounds
-
BioNTech AG and Genevant Sciences entered into a strategic partnership to develop five therapeutics to treat rare diseases.
-
BioNTech and Genevant Sciences Sign Strategic mRNA-Focused Partnership in Rare Diseases
7/10/2018
Partnership combines Genevant’s industry-leading delivery technology and BioNTech’s cutting-edge mRNA drug discovery platform to develop best-in-class therapeutics